The efficacy of oral ribavirin in the treatment of crimean-congo hemorrhagic fever in Iran.
We compared the mortality rate among patients suspected of having Crimean-Congo hemorrhagic fever (CCHF) who received treatment with oral ribavirin and those who did not. Ninety-seven (69.8%) of 139 treated patients suspected of having CCHF survived, and 61 (88.9%) of 69 treated patients with confirmed CCHF survived. The efficacy of oral ribavirin was 80% among patients with confirmed CCHF and 34% among patients suspected of having CCHF. Considering the limitations of observational studies, we conclude that oral ribavirin is an effective treatment for the hemorrhagic form of CCHF.
Mardani
M
M
Department of Infectious Diseases and Tropical Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. mmardani@hotmail.com
Jahromi
M Keshtkar
MK
Naieni
K Holakouie
KH
Zeinali
M
M
D000284:Administration, Oral; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D004196:Disease Outbreaks; D005260:Female; D003225:Hemorrhagic Fever Virus, Crimean-Congo / Q000187:drug effects; D006479:Hemorrhagic Fever, Crimean / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality; D006801:Humans; D007492:Iran / Q000453:epidemiology; D008297:Male; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome
D000998:Antiviral Agents; D012254:Ribavirin